Drug Interactions between ponesimod and ProQuad

GENERALLY AVOID: The administration of live, attenuated viral or bacterial vaccines during ponesimod therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Ponesimod causes reversible sequestration of lymphocytes in lymphoid tissues. A dose-dependent reduction in peripheral lymphocyte count to 30% to 40% of baseline values has been observed, which may increase the risk of infections. Vaccination may also be less effective during and for up to 1 to 2 weeks after discontinuation of ponesimod therapy.

MANAGEMENT: The use of live attenuated vaccines should be avoided during and for up to 1 to 2 weeks after ponesimod treatment, and ponesimod should be paused 1 week prior to and until 4 weeks after a planned vaccination. Patients without a healthcare professional confirmed history of varicella or without documentation of a full course of vaccination against varicella-zoster virus (VZV) should be tested for antibodies to VZV before initiating treatment with ponesimod. For antibody-negative patients, a full course of vaccination with varicella vaccine is recommended prior to treatment with ponesimod. In patients who have recently been vaccinated with varicella or other live vaccines, ponesimod therapy should be postponed for 4 weeks to allow the full effect of vaccination to occur. Administration of live attenuated vaccines in severely immunocompromised persons is generally considered a contraindication. Current local immunization guidelines and prescribing information for individual vaccines should be consulted for further information.

Switch to consumer interaction data

GENERALLY AVOID: The administration of live, attenuated viral or bacterial vaccines during ponesimod therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Ponesimod causes reversible sequestration of lymphocytes in lymphoid tissues. A dose-dependent reduction in peripheral lymphocyte count to 30% to 40% of baseline values has been observed, which may increase the risk of infections. Vaccination may also be less effective during and for up to 1 to 2 weeks after discontinuation of ponesimod therapy.

MANAGEMENT: The use of live attenuated vaccines should be avoided during and for up to 1 to 2 weeks after ponesimod treatment, and ponesimod should be paused 1 week prior to and until 4 weeks after a planned vaccination. Patients without a healthcare professional confirmed history of varicella or without documentation of a full course of vaccination against varicella-zoster virus (VZV) should be tested for antibodies to VZV before initiating treatment with ponesimod. For antibody-negative patients, a full course of vaccination with varicella vaccine is recommended prior to treatment with ponesimod. In patients who have recently been vaccinated with varicella or other live vaccines, ponesimod therapy should be postponed for 4 weeks to allow the full effect of vaccination to occur. Administration of live attenuated vaccines in severely immunocompromised persons is generally considered a contraindication. Current local immunization guidelines and prescribing information for individual vaccines should be consulted for further information.

Switch to consumer interaction data

GENERALLY AVOID: The administration of live, attenuated viral or bacterial vaccines during ponesimod therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Ponesimod causes reversible sequestration of lymphocytes in lymphoid tissues. A dose-dependent reduction in peripheral lymphocyte count to 30% to 40% of baseline values has been observed, which may increase the risk of infections. Vaccination may also be less effective during and for up to 1 to 2 weeks after discontinuation of ponesimod therapy.

MANAGEMENT: The use of live attenuated vaccines should be avoided during and for up to 1 to 2 weeks after ponesimod treatment, and ponesimod should be paused 1 week prior to and until 4 weeks after a planned vaccination. Patients without a healthcare professional confirmed history of varicella or without documentation of a full course of vaccination against varicella-zoster virus (VZV) should be tested for antibodies to VZV before initiating treatment with ponesimod. For antibody-negative patients, a full course of vaccination with varicella vaccine is recommended prior to treatment with ponesimod. In patients who have recently been vaccinated with varicella or other live vaccines, ponesimod therapy should be postponed for 4 weeks to allow the full effect of vaccination to occur. Administration of live attenuated vaccines in severely immunocompromised persons is generally considered a contraindication. Current local immunization guidelines and prescribing information for individual vaccines should be consulted for further information.

Switch to consumer interaction data

GENERALLY AVOID: The administration of live, attenuated viral or bacterial vaccines during ponesimod therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Ponesimod causes reversible sequestration of lymphocytes in lymphoid tissues. A dose-dependent reduction in peripheral lymphocyte count to 30% to 40% of baseline values has been observed, which may increase the risk of infections. Vaccination may also be less effective during and for up to 1 to 2 weeks after discontinuation of ponesimod therapy.

MANAGEMENT: The use of live attenuated vaccines should be avoided during and for up to 1 to 2 weeks after ponesimod treatment, and ponesimod should be paused 1 week prior to and until 4 weeks after a planned vaccination. Patients without a healthcare professional confirmed history of varicella or without documentation of a full course of vaccination against varicella-zoster virus (VZV) should be tested for antibodies to VZV before initiating treatment with ponesimod. For antibody-negative patients, a full course of vaccination with varicella vaccine is recommended prior to treatment with ponesimod. In patients who have recently been vaccinated with varicella or other live vaccines, ponesimod therapy should be postponed for 4 weeks to allow the full effect of vaccination to occur. Administration of live attenuated vaccines in severely immunocompromised persons is generally considered a contraindication. Current local immunization guidelines and prescribing information for individual vaccines should be consulted for further information.

Switch to consumer interaction data